A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus
| Autor: | Xiaoning Wu, Hui Ma, Min Cong, Tianhui Liu, Zhiliang Gao, Tong Li, Hui Zhuang, Yuanyuan Kong, Jialing Zhou, Ping Wang, Xue-En Liu, Hongxin Piao, Jiang Long, Yanhong Wang, Yongping Yang, Na Zeng, Qinghua Shang, Jian Huang, Xiaoyuan Xu, Xiaojuan Ou, Jidong Jia, Hong You, Guofeng Chen, Chitty Chen, Wen Xie, Tan Zongnan, Yameng Sun, Shanshan Wu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Liver Cirrhosis Male Hepatitis B virus medicine.medical_specialty Carcinoma Hepatocellular Cirrhosis Biopsy Population medicine.disease_cause Sensitivity and Specificity Biochemistry Gastroenterology Young Adult Liver disease Polysaccharides Internal medicine Biomarkers Tumor Genetics medicine Humans Metabolomics Early Hepatocellular Carcinoma education Molecular Biology Aged Retrospective Studies education.field_of_study business.industry Liver Neoplasms Middle Aged Hepatitis B medicine.disease Cross-Sectional Studies ROC Curve Hepatocellular carcinoma Metabolome Molecular Medicine Female Differential diagnosis business Biomarkers Biotechnology |
| Zdroj: | OMICS: A Journal of Integrative Biology. 24:415-423 |
| ISSN: | 1557-8100 |
| DOI: | 10.1089/omi.2020.0055 |
| Popis: | Early diagnosis of hepatic cancer is a major public health challenge. While changes in serum N-glycans have been observed as patients progress from liver fibrosis/cirrhosis to hepatocellular carcinoma (HCC), the predictive performance of N-glycans is yet to be determined for HCC early diagnosis as well as differential diagnosis from liver fibrosis/cirrhosis. In a total sample of 247 patients with hepatitis B virus-related liver disease, we characterized and compared the serum N-glycans in very early/early and intermediate/advanced stages of HCC and those with liver fibrosis/cirrhosis. Additionally, we performed a retrospective timeline analysis of the serum N-glycans 6 and 12 months before a diagnosis of the very early/early stage of HCC (EHCC). A predictive model was built, named hereafter as Glycomics-EHCC, incorporating the glycan peaks (GPs) 1, 2, and 4. The model showed a larger area under the receiver operating characteristic curve compared with a traditional model with the α-fetoprotein (0.936 vs. 0.731, respectively). The Glycomics-EHCC model had a sensitivity of 84.6% and specificity of 85.0% at a cutoff value of -0.39 to distinguish EHCC from liver fibrosis/cirrhosis. Moreover, the Glycomics-EHCC model was able to forecast a future EHCC diagnosis with a sensitivity and specificity over 90% and 85%, respectively, using the serum N-glycan biosignatures 6 or 12 months earlier when the patients were suffering from liver fibrosis/cirrhosis before being diagnosed with EHCC. This serum glycomic biosignature model warrants further clinical studies in independent population samples and offers promise to forecast EHCC and its differential diagnosis from liver fibrosis/cirrhosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|